Premature ejaculation: treatment update

Int J STD AIDS. 2010 Feb;21(2):77-81. doi: 10.1258/ijsa.2009.009434.

Abstract

Premature ejaculation (PE) is the most common male sexual problem worldwide affecting 22-38% of men. It has a significant morbidity both on patients and their partners, causing distress, anxiety and relationship difficulties. The mainstay of treatment is a combined approach using behavioural therapies and non-licensed medication such as topical anaesthetic preparations, selective serotonin re-uptake inhibitors and phosphodiesterase-5 inhibitors. In recent years, there has been a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations. This review provides an overview of current accepted treatments and emerging agents for the use in PE.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Anesthetics, Combined / therapeutic use
  • Anesthetics, Local / administration & dosage
  • Benzylamines / administration & dosage
  • Benzylamines / therapeutic use
  • Ejaculation*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Lidocaine / therapeutic use
  • Lidocaine, Prilocaine Drug Combination
  • Male
  • Naphthalenes / administration & dosage
  • Naphthalenes / therapeutic use
  • Phosphodiesterase 5 Inhibitors
  • Prilocaine / therapeutic use
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Sexual Dysfunction, Physiological / drug therapy*

Substances

  • Anesthetics, Combined
  • Anesthetics, Local
  • Benzylamines
  • Enzyme Inhibitors
  • Lidocaine, Prilocaine Drug Combination
  • Naphthalenes
  • Phosphodiesterase 5 Inhibitors
  • Serotonin Uptake Inhibitors
  • Prilocaine
  • Lidocaine
  • dapoxetine